The tricky part is figuring out where to start, what you're signing up for, and whether it's worth your time. This guide walks through the current landscape of diabetes research in the U.S., what each phase of a trial involves, and how to find studies near you.
The State of Diabetes Research in America
More than 38 million Americans live with diabetes, and researchers across the country are testing everything from GLP-1 receptor agonists to stem cell therapies designed to replace insulin-producing beta cells. At the 2026 Scientific Sessions of the American Diabetes Association in New Orleans, investigators presented phase 2 results for a dual GLP-1/GIP receptor agonist being studied in type 1 diabetes — a notable shift, since these drugs have primarily been developed for type 2. The trial showed improved blood glucose control and weight reduction in participants who still required insulin but struggled with weight gain and cardiovascular risk.
Meanwhile, Vertex Pharmaceuticals continues its VX-880 islet cell replacement program for people with type 1 diabetes who experience severe hypoglycemia or impaired awareness of hypoglycemia. That study spans 27 trial locations across Illinois, Florida, California, Maryland, Texas, Massachusetts, Wisconsin, and Pennsylvania, plus sites in Canada and Europe.
What does this mean for you? If you're living with diabetes, you have more options for research participation than ever before — but the process requires patience and a clear understanding of what each study demands.
How Diabetes Clinical Trials Actually Work
Clinical trials in the U.S. follow a structured pathway governed by the Office for Human Research Protections and reviewed by Institutional Review Boards at each site. Your health information stays protected under HIPAA, and you can withdraw from any study at any time without penalty.
The four phases matter more than most people realize:
Phase 1 involves small groups, often 20 to 80 participants, focused on safety, dosing, and how the drug moves through the body. For diabetes drugs, this phase may include healthy volunteers or people with diabetes depending on the compound's profile.
Phase 2 expands to several dozen to several hundred participants with diabetes. Researchers evaluate effectiveness at different doses and compare results against placebo or existing treatments. The dual GLP-1/GIP agonist study mentioned earlier is in this phase.
Phase 3 is the big one — hundreds or thousands of participants across multiple sites, designed to confirm efficacy, monitor side effects, and compare the new treatment against standard care. The STRIDE trial of semaglutide in people with type 2 diabetes and peripheral artery disease enrolled 792 patients across 112 sites in 20 countries, demonstrating improved walking capacity in patients with limited treatment options.
Phase 4 happens after FDA approval, tracking long-term safety and real-world effectiveness.
What Participation Actually Looks Like
Most people imagine clinical trials as sterile hospital rooms and endless paperwork. The reality is more practical. Expect more frequent contact with the medical system than usual: regular clinic visits, detailed lab work, continuous glucose monitoring, and thorough documentation of how you feel.
The process starts with pre-screening — an online form or phone interview to assess basic eligibility. Common criteria include diabetes type, age, HbA1c levels, duration of diagnosis, and current treatment history. If you pass pre-screening, you'll attend an in-person screening visit with comprehensive blood work and sometimes imaging. This screening is typically compensated and never obligates you to enroll.
Once enrolled, you'll sign an informed consent document that explains the study's purpose, procedures, potential risks, and your rights. This is not a casual signature — researchers walk through it with you, and you should ask every question you have.
Realistic Expectations About Compensation
Compensation for diabetes clinical trials varies widely based on study phase, duration, and the number of required visits. Most studies reimburse for time and travel, with amounts reflecting the study's complexity. Phase 1 and 2 trials generally offer more modest compensation because they require fewer visits, while longer phase 3 studies involving continuous glucose monitoring or frequent clinic visits provide higher reimbursement to offset the time commitment.
Maria from Phoenix, a 54-year-old with type 2 diabetes, participated in a 12-month trial evaluating a once-weekly injectable. "The clinic visits felt like a second job some weeks," she says. "But my A1C dropped from 8.4 to 6.9, I had access to an endocrinologist who actually listened, and the travel reimbursement covered my gas." Her experience reflects a common pattern: compensation rarely makes anyone rich, but it covers costs and provides access to specialists and cutting-edge monitoring technology.
One important note: compensation should never be your primary reason for participating. The value lies in access to investigational treatments, close medical monitoring, and contributing to research that could help millions of people.
Where to Find Diabetes Clinical Trials Near You
ClinicalTrials.gov remains the definitive resource. Run by the U.S. government, it catalogs federally and privately supported studies across the country. Search by condition (type 1 diabetes, type 2 diabetes, diabetic neuropathy), location, and eligibility criteria. Each listing explains compensation, time commitment, and whether the study is actively recruiting.
Beyond the federal database, consider these pathways:
- Major academic medical centers — Mayo Clinic, Johns Hopkins, UCSF, and Joslin Diabetes Center run numerous trials and often post openings on their research pages.
- The American Diabetes Association maintains a research section with trial listings and press releases about new studies.
- Breakthrough T1D (formerly JDRF) funds and tracks type 1 diabetes research specifically, including cell therapy and immunotherapy trials.
- UW Medicine Diabetes Institute in Seattle recently launched a trial recruiting adults recently diagnosed with type 1 diabetes to study a drug that may protect insulin-producing cells — a reminder that newly diagnosed individuals have unique opportunities.
- Local diabetes clinics and endocrinology practices frequently partner with research organizations. Ask your doctor whether they know of any recruiting studies in your area.
For people in underserved communities, the landscape is slowly improving. Programs like the Diabetes Care Management Program at safety net clinics are incorporating continuous glucose monitors and remote patient monitoring into research settings, with some studies specifically designed around the needs of populations historically underrepresented in clinical trials.
A Step-by-Step Action Plan
1. Start with a self-assessment. Write down your diabetes type, diagnosis date, current medications, most recent HbA1c, and any complications you manage. This information speeds up the pre-screening conversation.
2. Search strategically. Use ClinicalTrials.gov with terms like "type 2 diabetes clinical trials [your city]" or "diabetes research studies near me." Narrow by phase and study type — interventional studies test new treatments, while observational studies track outcomes without changing your care.
3. Contact the study coordinator. Every trial listing includes contact information. Prepare your questions: How many visits are required? What does the treatment involve — injection, pill, device? Is there a placebo group? What happens after the trial ends?
4. Review the informed consent carefully. This document outlines everything: the investigational product, potential side effects, compensation, and your right to withdraw. Take it home. Read it twice. Bring it to your doctor.
5. Talk to your regular care team. Your endocrinologist or primary care physician can help you assess whether a trial fits your health situation. Some trials require coordination between the research team and your usual providers.
6. Consider travel logistics. Some studies require weekly visits; others are monthly. For rural residents, the University of Tennessee Health Science Center's HEAL Diabetes-USA study explores weight loss interventions for diabetes remission, and telehealth-based trials are becoming more common. Look for studies that match your geographic reality.
Questions Worth Asking Before You Commit
Not every trial is the right fit, and that's okay. Before you sign anything, ask the coordinator:
- Who pays for the investigational drug and related tests?
- What happens to my diabetes management if I need to pause the study?
- Will I learn my results, including whether I received the active treatment or placebo?
- How does the study handle emergency medical situations?
- What follow-up care is available after the trial concludes?
These questions aren't just practical — they signal to the research team that you understand the commitment, which works in your favor.
Weighing the Trade-Offs
Every clinical trial carries unknowns. The investigational drug might not work for you. You might receive a placebo. Side effects can occur, and in the case of stem cell therapies like VX-880, participants must take antirejection drugs that carry their own risks — several participants in earlier studies withdrew due to those side effects.
But for many people with diabetes, the potential benefits outweigh the uncertainty: access to treatments years before they reach the market, intensive monitoring that catches problems early, and the quiet satisfaction of advancing science that could change how diabetes is treated for the next generation.
| Trial Type | Typical Example | Time Commitment | What You Get | Main Considerations |
|---|
| Phase 1 safety study | New oral drug for type 2 diabetes | Several weeks, frequent visits | Close monitoring, modest compensation | Higher uncertainty about effectiveness |
| Phase 2 efficacy study | Dual GLP-1/GIP agonist in type 1 diabetes | 3-6 months | Investigational treatment, specialized care | Placebo possible, side effect monitoring |
| Phase 3 large trial | Semaglutide for diabetes with PAD | 6-24 months | Long-term access, comprehensive testing | Significant time investment |
| Observational study | CGM + remote monitoring program | Varies | Real-world data, no experimental treatment | No access to investigational drugs |
| Cell therapy trial | VX-880 islet cell replacement | Long-term follow-up | Potential for major improvement | Antirejection drugs, higher risk profile |
Making the Call
The decision to join a diabetes clinical trial is deeply personal. Some people participate because standard treatments haven't worked well enough. Others want to give back to a research community that helped them. Many simply want to learn more about their own condition while contributing to knowledge that could help their children or grandchildren.
Start by exploring what's recruiting near you. Talk to your doctor. Ask hard questions. And remember — saying yes to a screening visit is not the same as committing to the trial. You hold the power to stop at any stage.
The next breakthrough in diabetes treatment is being tested right now, at a research site somewhere in the United States. It could involve people just like you. The only way to know if you belong in that number is to look at what's available and decide for yourself.
研究の知恵